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Summary
Background: Current pain management is limited, in partic-
ular, with regard to chronic pain. In an attempt to discover
novel analgesics, we combined the approach developed to
characterize traditional Chinese medicine (TCM), as part of
the ‘‘herbalome’’ project, with the reverse pharmacology
approach aimed at discovering new endogenous transmitters
and hormones.
Results: In a plant used for centuries for its analgesic proper-
ties, we identify a compound, dehydrocorybulbine (DHCB),
that is effective at alleviating thermally induced acute pain.
We synthesize DHCB and show that it displays moderate
dopamine receptor antagonist activities. By using selective
pharmacological compounds and dopamine receptor
knockout (KO) mice, we show that DHCB antinociceptive
effect is primarily due to its interaction with D2 receptors, at
least at low doses. We further show that DHCB is effective
against inflammatory pain and injury-induced neuropathic
pain and furthermore causes no antinociceptive tolerance.
Conclusions: Our study casts DHCB as a different type
of analgesic compound and as a promising lead in pain
management.Introduction
Pain reduces the quality of life and imparts high health costs
and economic loss to society. Pain can be differentiated into
mechanical pain, which represents an acute response to a
mechanical insult; inflammatory pain, which is associated
with tissue damage and the infiltration of immune cells; and
neuropathic pain, which is caused by damage to the nervous8These authors contributed equally to this work
*Correspondence: liangxm@dicp.ac.cn (X.L.), ocivelli@uci.edu (O.C.)system [1]. Pain sensation is transmitted by afferent neurons
from the periphery to the spinal cord and from there to the
brain, with feedback loops modifying the input [2]. Current
pain management strategies rely primarily on anti-inflam-
matory and antinociceptive drugs. The prevalent anti-inflam-
matory drugs are the nonsteroidal anti-inflammatory drugs
(NSAIDs), including the COX-2 selective inhibitors. They are
the first line of therapy against low or moderate pain, followed,
if unsuccessful, by the more potent opiate drugs. The opiates
are the most common antinociceptive drugs and are effective
for 70%–80% of patients. This class of drugs is however
plagued by side effects. They reduce gastrointestinal motility,
affect blood pressure, and induce tolerance, dependence, and
at high doses respiratory depression [3]. Neuropathic pain is
managed poorly; anticonvulsants and antidepressants are
sometimes used, but with limited results [4]. Therefore, the
search for new analgesic compounds that present therapeutic
alternatives is important.
For over 7,000 years, various extracts of natural products,
mostly plants, have served as analgesics. These extracts offer
an opportunity to identify new analgesic compounds. They
contain numerous components, but only some display anal-
gesic properties [5]. Identifying new ones requires a strategy
that combines analytical purification and pharmacological
analyses. We chose an approach that takes advantage of the
purification efforts that have been developed to globalize
and modernize traditional Chinese medicines (TCMs) as part
of the ‘‘herbalome’’ project [6, 7] and of the reverse pharma-
cology approach developed to identify compounds acting at
G protein-coupled receptors (GPCRs) [8, 9]. We applied this
approach to plant extracts and receptors known to display
antinociceptive properties.
Results
Purification, Identification and Pharmacological
Characterization of Dehydrocorybulbine, an Alkaloid from
Corydalis yanhusuo W. T. Wang
Ten TCMs known for their analgesic properties were screened
oncells expressing themopioid receptor. These includedCom-
miphora myrrha (Nees) Engl., Macleaya cordata (Willd.) R.Br.,
Stephania japonica (Thunb.) Miers, Stephania tetrandra S.
Moore, Huperzinaserrata (Thumb.)Trev, Anisodus tanguticus
(Maxinowicz) Pascher,Nandina domestica,Carthamus tinctor-
ius L, Lonicera japonica Thunb, and Corydalis yanhusuo
(C. yanhusuo). Approximately 500 high-performance liquid
chromatography (HPLC) fractionated samples were tested for
their ability to activate the m opioid receptor. However, only
one fraction in C. yanhusuo was able to induce a reproducible
receptor-dependent intracellular Ca2+mobilization (Figure 1A).
By using a novel stationary phase [10, 11], this fraction,
which contains a series of structurally related alkaloids difficult
to be resolved by conventional chromatography, was effi-
ciently purified and its active component was successfully
isolated (Figure 1B). The structure of this component was
elucidated by UV, mass spectrometry, nuclear magnetic
resonance (NMR), and single X-ray crystallography (see the
Supplemental Results available online) and was determined
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Figure 1. DHCB Isolation and Characterization
(A) Elution profile of C. yanhusuo extract on a C18HCE reverse-phase HPLC
column (4.63 150mm, 5 mm) and activities of 80 fractions (0.5min) tested for
their abilities to induce intracellular Ca2+ mobilization in HEK293T cells ex-
pressing m opioid receptor. Elution was performed with a linear gradient
that was from 5% to 15% CH3CN in 30 min then from 15% to 95% CH3CN
in 10 min. The flow rate was 1 ml/min. The relative activities represent the
ratio between the fluorescence intensities obtained with m- andmock-trans-
fected cells. Fraction 42 (indicated by an arrow) was most active.
(B) DHCB purification and structure elucidation. Fraction 42 was further pu-
rified by two purification steps. The last step was performed on an analytical
C18HCE column (4.6 3 150 mm, 5 mm) using an isocratic elution of 15%
CH3CN. The insert HPLC profile represents the purity of purified DHCB.
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118to be dehydrocorybulbine (DHCB; structure shown in Fig-
ure 1B, insert).
Purified DHCB induced a dose-dependent Ca2+ change in
m-expressing cells (Figure S1A, left panel) with a half-maximum
response (EC50) of 100 mM and failed to induce a detectable
response in parental cells. This activity is antagonized by
naloxone (Figure S1A, right panel). DHCB showed marginal
activity at d and k opioid receptors (Table 1).
Synthesis of DHCB
DHCB was originally isolated from Corydalis ambigua var
amurensis in 1964 [12], but its biological andmedicinal proper-
ties have remained unknown. It has also never been synthe-
sized. In order to generate sufficient amounts, we synthesized
DHCB through a four-step process (Figure 2). Berberine was
used as a starting material for a selective reduction reaction,
in which NaBH4 was used as a reducing agent and methanol
as the solvent. The key intermediate product 2 was obtained
with a 76% yield by adding dropwise NaBH4 in 5% NaOH in
10 min, and the total amount of NaBH4 was strictly controlled.Product 2 was allowed to react with 37% formaldehyde in a
mixture of EtOH and HOAc and then acidified with 2 N HCl to
provide the key intermediate product 3 with a 90% yield.
Product 3 was reacted with phloroglucinol in H2SO4 (60%) at
90C–95C to yield product 4. The concentration of H2SO4
(55%–65%) and reaction time (20–30 min) are key factors
during this step. Macroporous resins (XAD-4 and D152) were
employed to separate product 4 from the reaction mixture
(31% yield). The desired compound (DHCB) was obtained
through a selective methylation of product 4, in which chloro-
methyl methyl ether was used to selectively protect the
phenolic hydroxyl at 3 position, and then the phenolic hydroxyl
at 2 position was methylated by methyl p-toluenesulfonate,
followed by a deprotection with 2 N HCl. The final product
was purified through preparative HPLC. This approach is
efficient and yielded 12.5% purified material from a readily
available berberine. The synthesized compound was found
to be identical to purified DHCB in chromatographic behavior
and spectra data. To our knowledge, this is the first report of
DHCB synthesis.
DHCB Is Antinociceptive in an Acute Pain Model
C. yanhusuo is used for its antinociceptive properties [13].
Since strong sedation may influence assessment of pain-
related behaviors and since most analgesics carry sedative
effects, DHCB was first tested for its potential sedative prop-
erties by monitoring its effects on locomotor activity and in
the rotarod assay. The results show that DHCB is not sedative
at doses of 10 mg/kg or lower (Figure S1B). We consequently
used 10 mg/kg as the nonsedative threshold dose.
DHCB’s antinociceptive activity was tested in the tail-flick
assay, which records responses to a thermal stimulus. These
experiments were carried out using a moderate 7–8 s baseline
topermit lowantinociception detection. As shown in Figure 3A,
DHCB was found to induce antinociception in a dose-depen-
dent manner. It shows a potent effect and has a longer lasting
antinociceptive property at high doses (at least 3 hr) and re-
mained antinociceptive at the nonsedative dose (10 mg/kg).
Pharmacokinetic analyses have revealed that DHCB remains
in the plasma at relatively high concentrations at least 3 hr after
intraperitoneal (i.p.) injection (Figure S1C). In addition, prelim-
inary in vitro metabolism analyses show that DHCB is not
metabolized in phase I, but is slowly metabolized into two
glucuronidated products in phase II (Figure S1D). These find-
ings indicate that DHCB is able to penetrate the blood-brain
barrier and has favorable pharmacokinetic properties.
The Mechanism of DHCB’s Antinociceptive Activity
DHCB’s weak activity at the m receptor prompted us to carry
out a survey of the properties of known alkaloids in
C. yanhusuo. L-tetrahydropalmatine (l-THP), a primary active
constitute in C. yanhusuo, has been shown to display dopa-
mine receptor antagonism and exert analgesic effects [14,
15]. Because DHCB and l-THP (structure shown in Figure S1E)
are structurally similar, their activities were compared at the
five dopamine receptor subtypes. We found that both DHCB
and l-THP behave as antagonists (Figure S1F). As summarized
in Table 1, DHCB exhibits micro- or submicromolar affinities to
all five dopamine receptors and displays its highest affinity to
the D2 receptor. When compared to l-THP, DHCB shows
higher or comparable affinities to the D2-like and lower
affinities to the D1-like receptors (Table 1). Consistent with a
previous report [16], l-THP showed no activity at the m opioid
receptor.
Table 1. DHCB In Vitro Activities at the m Opioid and Dopamine Receptors and Comparison to l-THP
Opioid Agonist (EC50, mM) Dopamine Antagonist (IC50, mM)
m d k D1 D2 D3 D4 D5
DHCB 100 (74w136) >500 >500 2.16 (1.4w3.2) 0.52 (0.24w1.12) 2.4 (1.3w4.5) 8.4 (4.6w15) 0.73 (0.25w2.1)
l-THP NA NA NA 0.51 (0.31w0.82) 0.32 (0.24w0.41) 9.7 (4.9w19) 9.7 (6.8w14) 0.19 (0.11w0.32)
NA, not applicable.
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activity, we first ascertained whether its antinociceptive role
in vivo can be inhibited by naloxone. As shown in Figures 3B
and S1G, the antinociception induced by DHCB (10 mg/kg) in
the tail-flick assay was not found to be antagonized by
naloxone, which is in accord with its activity at the m opioid
receptor in vitro.
Next, we tested whether dopamine D1 and/or D2 receptors
are involved in DHCB antinociception. As shown in Figure 3C
(left panel), SKF-38393, a selective D1 agonist, was unable to
block the effect of DHCB (10 mg/kg) in the tail-flick assay. In
contrast, quinpirole, a selective D2 agonist, significantly
reversed DHCB antinociception (Figure 3C, right panel). To
further study the role of dopamine D2 receptor in mediating
DHCB antinociception, we tested its effects on D2 receptor
knockout (D2KO) mice. Wild-type (WT) and D2KO animals
display similar tail-flick latency baselines (Figure 3D). DHCB
at a nonsedative dose (5 mg/kg, shown in Figure S1H) induced
an antinociceptive response in WT animals, but not in D2KO
mice (Figure 3D). This shows that DHCB antinociceptive effect
is primarily, at least at low doses, due to its interaction with D2
receptors, also raising the possibility that this may also be the
site of l-THP action [14, 15].DHCB Is Antinociceptive in Inflammatory and Neuropathic
Pain Models
To ascertain and extend our understanding of its antinocicep-
tive efficacy, we tested DHCB in the formalin assay, a test
designed to assess both acute and persistent inflammatory
pain responses. The assay produces a distinct biphasic
response. Phase I (early phase) occurs within the first 5 min
after formalin injection and corresponds to acute neurogenic
pain. Phase II (10–50 min, late phase) corresponds to inflam-
matory pain and is inhibited by nonsteroidal anti-inflammatory
drugs. As shown in Figure 4A, DHCB caused a significant
reduction in the time spent licking in the early (p < 0.05) and21
NaBH4, K2CO3
CH3OH, r.t.
(1) MOMCl, DMF, K2CO3,  0 ć
(2) MeOTs, r.t.
(3) HCl, r.t.
55%
%09%67
HCHO, HOAc
80% EtOH,  refluxlate (p < 0.001) phases. This effect is dose dependent, effective
at a nonsedative dose, and comparable to that of morphine at
high doses.
Chronic neuropathic pain is a common clinical problem
affecting over 50 million people in the United States [17]. The
management of neuropathic pain remains a major clinical
challenge due to the poor efficacies and severe side effects
of conventional analgesics. The assay commonly used to
model neuropathic pain is spinal nerve ligation, which induces
allodynia as measured by mechanical sensitivity in the von
Frey hair stimulation assay and hyperalgesia as measured by
thermal sensitivity in the Hargreave-type hot box. We show
that DHCB at a nonsedative dose (10 mg/kg, determined in
Figure S2A) significantly attenuates mechanical allodynia in
response to von Frey stimulation (Figure 4B, left panel) and
hyperalgesia by hot box (Figure 4B, right panel).
Taken together, these data demonstrate that DHCB is
effective at suppressing responses to chemically induced, in-
flammatory-derived, and injury-induced pain. Further studies
will be needed to determine whether these effects also depend
on DHCB dopamine D2 receptor antagonist activity.
DHCB Does Not Cause Antinociceptive Tolerance
The fact that DHCB exerts its antinociceptive effects through
dopamine D2 receptors but not the m opioid receptor led us
to test it for antinociceptive tolerance. Mice were subjected
to daily DHCB administrations over a 7-day period and
monitored for their responses in the tail-flick assay (Figure 5).
Unlike with morphine (10 mg/kg), mice did not develop toler-
ance to DHCB (10 mg/kg).
Discussion
Management of chronic pain is an unmet medical need. Use of
conventional drugs is often neither effective nor free of side
effects. To find new natural analgesics, we combined the3
4
31%
phloroglucinol,
60% H2SO4, 90-95 ć
Figure 2. DHCB Synthesis Pathway
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Figure 3. Antinociceptive Effects of DHCB in the
Tail-Flick Assay and Its Mode of Action
(A) Antinociceptive effects in the tail-flick assay.
CD1 mice were used in this assay. Left: time
course of the tail-flick latencies (n = 8-24). Two-
way ANOVA revealed significant drug effect
(F3,67 = 145.6, p < 0.0001), time effect (F4,268 =
72.84, P < 0.0001), and drug 3 time interaction
(F12,268 = 27.09, p < 0.0001); Right: dose-
response effect of DHCB (5, 10, or 40 mg/kg,
i.p.) on tail-flick latency 60 min after administra-
tion (n = 8–24). One-way ANOVA revealed signif-
icant drug effect (F4,80 = 82.74, p < 0.0001).
Bonferroni post hoc tests: drug versus saline,
*p < 0.05, **p < 0.01, ***p < 0.001.
(B) Naloxone (1 mg/kg, i.p.) effect on DHCB
(10 mg/kg, i.p.)-induced antinociception in the
tail-flick assay (n = 6–8). Naloxone was injected
right before DHCB administration. Tail-flick
latency was measured 30 min after DHCB
administration. CD1 mice were used in this
assay. One-way ANOVA revealed significant
drug effect (F4,30 = 62.44, p < 0.0001). Bonferroni
post hoc tests: drug versus saline, ***p < 0.001;
morphine versus morphine plus naloxone,
###p < 0.001; N.S., not significant, p > 0.05.
(C) Time course of SKF-38393 (1 mg/kg, i.p, left
panel) and quinpirole (0.5 mg/kg, i.p. right panel)
effects on DHCB (10 mg/kg, i.p.)-induced
response in the tail-flick assay (n = 7–8). CD1
micewere used in this assay. SKF-38393 or quin-
pirole was injected 30 min before DHCB. Tail-
flick latenciesweremeasured 30 and 60min after
administration of DHCB. Two-way ANOVA
revealed significant drug effect (left panel:
F3,27 = 56.21, p < 0.0001; right panel:F3,27 =
21.28, p < 0.0001), time effect (left panel: F2,54 =
39.40, p < 0.0001; right panel:F2,54 = 33.43, p <
0.0001), and drug 3 time interaction (left panel:
F6,54 = 14.19, p < 0.0001; right panel: F6,54 =
16.69, p < 0.0001). Bonferroni post hoc tests:
drug versus saline, **p < 0.01, ***p < 0.001;
DHCB versus DHCB plus quinpirole, ###p <
0.001; N.S., not significant.
(D) Time course of DHCB (5 mg/kg, i.p.) effects in
D2KO mice assessed in the tail-flick assay (n =
6-7). The D2KO mice used in this study were
backcrossed in a 50%C57Bl/6/50%129SVback-
ground for six consecutive generations with pure
C57Bl/6 mice resulting into 98.5% C57Bl/6%–
1.5%129 SV animals. Age-matched wild-type
littermates with the same genetic background
were used as control animals. Tail-flick latencies
weremeasured 30 and 60min following adminis-
tration of DHCB (5 mg/kg, i.p.). Two-way ANOVA
revealed significant drug effect (F3,22 = 32.99, P <
0.0001), time effect (F2,44 = 10.02, p = 0.0003) and
drug3 time interaction (F6,44 = 10.59, P < 0.0001).
Bonferroni post hoc tests: DHCB/WT versus
saline/WT groups: ***p < 0.001; DHCB/WT versus
DHCB/D2KO groups: ###p < 0.001; N.S., not
significant, p > 0.05.
In all cases, data are means 6 SEM. See also
Figure S1.
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120herbalome and the reverse pharmacology approaches. Out of
500 HPLC fractions derived from ten TCMs, only one fraction,
isolated from C. yanhusuo, was found active at the opioid
receptor. Of the ten TCMs that were screened, C. yanhusuo
is the only one belonging to the Papaveraceae family, which
includes opium (Papaver somniferum) and thus may be the
only one that has retained compounds that act at opioidreceptors. It is also worthwhile to mention that through this
approach, we may have missed several analgesic compounds
that do not behave as m receptor agonists.
We then took advantage of novel separation techniques to
purify this fraction and to identify DHCB as its active compo-
nent. C. yanhusuo preparations have been historically em-
ployed for the treatment of various pains and are officially
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Figure 4. Antinociceptive Effects of DHCB in In-
flammatory Pain and Neuropathic Pain Models
(A) Effects of DHCB in the formalin assay (n = 9–
24). CD1 mice were used in this assay. Formalin
(25 ml, 5% in saline) was injected into the dorsal
surface of the right hind paw 15 min after DHCB
administration. Left panel: time course effects.
Two-way ANOVA revealed significant drug effect
(F4,74 = 63.47, p < 0.0001), time effect (F9,666 =
44.54, p < 0.0001), and drug 3 time interaction
(F36,666 = 5.09, p < 0.0001). Bonferroni post hoc
tests: drug versus saline, *p < 0.05, **p < 0.01,
***p < 0.001. Right panel: Cumulative effects in
phase I (0–5 min) and phase II (10–50 min) of the
formalin assay. One-way ANOVA indicated sig-
nificant drug effect in both phase I (F4,76 =
71.93, p < 0.0001) and phase II (F4,76 = 45.96,
p < 0.0001). Dunnett’s post hoc tests: drug ver-
sussaline, *p < 0.05, **p < 0.01, ***p < 0.001.
(B) Effects of DHCB (10 mg/kg, i.p.) after spinal
nerve ligation (SNL). 129/sv mice were used in
this assay. Mice were injected with DHCB about
2 weeks after SNL when all injured mice have
developed hindpaw mechanical and thermal hy-
persensitivies on the injured side. Left panel: ef-
fects of DHCB in Von Frey assay. Two-way
ANOVA revealed significant drug effect (F1,14 =
18.88, p = 0.0007), time effect (F6,84 = 10.53, P <
0.0001), and drug 3 time interaction (F6,84 =
4.11, p = 0.0012). Bonferroni post hoc tests:
contralateral versus ipsilateral, *p < 0.05, **p <
0.01, ***p < 0.001. Right panel: effects of DHCB
in hot box assay (n = 8). Two-way ANOVA indi-
cated only significant main effect of treatments
(F1,14 = 17.44, p = 0.0009). Bonferroni post hoc
tests: contralateral versus ipsilateral, *p < 0.05.
In all cases, data are means6 SEM. See also Fig-
ure S2.
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121listed in the Chinese Pharmacopoeia [13]. DHCB has however
never been synthesized, although a few studies have been
carried out on berberine analogs [18, 19]. As shown in Figure 2,
we synthesized the key intermediate products 3 and 4 based
on previous reports describing the synthesis of berberine
analogs [18, 19]. The major challenge was to selectively meth-
ylate the phenolic hydroxyl at 2 position but not at 3 position in
the intermediate product 4. The issue resides with the phenolic
hydroxyl at 3 position, which is easy to methylate because the
N+ renders the hydroxyl at 3 position more acidic and thus
more able to accept 2CH3. Our strategy was to find a reagent
able to protect the phenolic hydroxyl at 3 position. Several re-
agents were tried, and chloromethyl methyl ether was found to
be efficient. After methylation of the hydroxyl at 2 position, the
deprotection at 3 positionwas performed using 2 NHCl. DHCB
synthesis proceeds in four steps and leads to 12.5% overall
yield from a readily available berberine.
Synthetic DHCB was used to show that it is effective at alle-
viating thermally as well as chemically induced acute pain and
inflammatory-induced persistent tonic pain. It is effective at
doses that do not induce sedation and at high doses exerts
an antinociceptive response similar to that obtained with
morphine. Furthermore, DHCB is effective at relieving injury-
induced neuropathic pain. Because DHCB antinociceptive
effects are displayed in both the acute and the inflammatory
phases of the formalin assay, its activity may result from direct
effects on the central nervous system [20, 21]. Indeed, our
pharmacokinetic and preliminary in vitro metabolism analyses
indicate that DHCB is able to penetrate the blood-brain barrier.
DHCB remains present in the brain and plasma at least 3 hr,which correlates with the duration of its antinociceptive action
in the tail-flick assay. It should be mentioned that it did not
exhibit such a long-lasting duration in the neuropathic pain
model, which may reflect differences in sensitivity between
the mouse strains used in these two assays.
Our results also indicate that DHCB displays advantageous
activities over l-THP, which is another antinociceptive compo-
nent of C. yanhusuo extract. DHCB is more analgesic than
l-THP in the tail-flick at a nonsedative dose (Figure S1I) and
is less sedative (Figure S1B). L-THP has been previously
thought to account for most of the analgesic properties of
C. yanhusuo. Because both DHCB and l-THP are present at
comparable levels in C. yanhusuo (0.018% and 0.025%,
respectively), it is reasonable to believe that not only l-THP,
but also DHCB, is responsible for the analgesic effects of
C. yanhusuo extracts.
To gain further insight on themechanismbywhich DHCBex-
erts its antinociceptive responses, we first show that in vitro it
behaves as a weak agonist at the m opioid receptor and an
antagonist at the dopamine receptors. We then show that
in vivo DHCB displays a naloxone resistant antinociceptive
response in the tail-flick test, as well as in formalin assay (Fig-
ure S2B). This is expected because of its low affinity for the m
opioid receptor, which indicates that DHCB cannot reach an
effective concentration to activate this receptor in vivo. The
affinities of DHCB to the dopamine receptors are more than
one hundred times higher than that to the m opioid receptor.
Therefore, the role of DHCB in vivo was first analyzed by using
selective dopamine D1 and D2 receptor agonists at doses that
do not affect antinociception in the tail-flick assay. We found
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Figure 5. Lack of Antinociceptive Tolerance of DHCB
Repeated i.p. injections of 10 mg/kg DHCB for 7 consecutive days induced
no antinociceptive tolerance (n = 6–8). CD1 mice were used in this study.
Two-way ANOVA revealed significant drug effect (F2,17 = 125.3, p <
0.0001), time effect (F4,68 = 55.46, p < 0.0001), and drug 3 time interaction
(F8,68 = 36.4, p < 0.0001). Bonferroni post hoc tests: drug versus saline,
*p < 0.05, **p < 0.01, ***p < 0.001. Data are means 6 SEM.
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122that quinpirole, a D2 receptor agonist, antagonizes DHCB anti-
nociceptive response while SKF-38393, a D1 receptor agonist,
does not. This result was extended and confirmed by using
D2KO mice. In these mice, the antinociceptive effects of
DHCB are strongly decreased, which indicates that its action
is mediated primarily through its inhibition of the dopamine
D2 receptor. This experimentwas carried out using a nonseda-
tive dose of DHCB and thus does not reflect a locomotion-
related response. It has been reported that dopamine D2
receptor activity in the striatum is associated with pain sensi-
tivity and painmodulatory capacity in healthy subjects [22, 23].
Interestingly, both dopamine D2 receptor agonists [24–28] and
antagonists [29–31] have been reported to exert analgesic
properties. Preferential presynaptic dopamine D2 receptor
binding by some of the D2 antagonists might explain these
seemingly contradictory propositions [31, 32]. Antagonists
selective to the presynaptic D2 receptors would increase
dopamine release and in turn increase antinociception. In
this respect, low doses of amisulpride, a selective antagonist
of dopamine D2/D3 receptor with selective preference for
presynaptic dopamine autoreceptors, significantly increase
tail-flick latency in mice [31]. Further studies will be needed
to determine whether the antinociceptive effects of DHCB
are regulated by presynaptic dopamine D2 receptors.
Because one of the major drawbacks of the narcotic analge-
sics is development of tolerance, we tested DHCB behavior
versus antinociceptive tolerance. We show that repeated
DHCB administrations do not lead to development of toler-
ance and thus that DHCB may present advantages over
morphine in chronic pain treatment. Due to its interaction
with dopamine receptors, further studies should be carried
out to determine whether DHCB exhibits the other side effects
of the neuroleptics.
The strategy that we adopted to ultimately isolate DHCB
can be applied to any natural source and to many re-
ceptors. It therefore has the potential to discover not only
new analgesics, but also numerous other naturally occurring
active compounds. In view of the interest in pharmacotherapy
for finding compounds with multipharmacological profiles,
this study suggests that natural products still hold great
promise.Experimental Procedures
Purification, Identification, and Synthesis of DHCB
The fractionation of the crude n-butanol extract was performed on an analyt-
ical C18HCE column (4.63 150mm, 5 mm)with an AllianceHPLC system that
consisted of aWaters 2695HPLCpumpand aWaters 2996 photodiode array
detector. The mobile phases were composed of CH3CN (phase A) and 0.1%
formicacidaqueous (phaseB),with agradient of 5%Ato15%A in30minand
then to 95% A in 10 min. The flow rate was 1.0 ml/min, and the column tem-
perature was maintained at 30C. The amount of sample loading is 6 mg per
injection. The fractions were collected with a Waters Fraction Collector III at
intervals of 0.5min/fraction. After the active fraction (F42) was found, 1.0 g of
the crude sample was fractionated on a semipreparative C18HCE column
(203 150 mm, 10 mm), with a similar HPLC method mentioned above but at
20.0 ml/min. The active fraction was pooled, and it was further separated
on the analytical C18HCE column with an isocratic elution of 15% CH3CN.
Finally, 5.8mg (yield 0.01%, dryweight) of the single compoundwaspurified.
Structure elucidation of the isolated active compound was carried out by
using various spectral techniques. HRESIMS were recorded on a Q-TOF
system (Waters). NMR spectra were obtained on Bruker AV400 spectrom-
eter. Single crystal was obtained in the perchlorate form of DHCB by slow
volatilization of its methanol solution. X-ray diffraction was performed
with a Bruker Apex II CCD diffractometer equipped with a fine-focus
sealed-tube X-ray source (MoKa radiation, graphite monochromated).
Structures were solved by direct methods using SHELXTL and were refined
by full-matrix least-squares on F2 using SHELX-97. Nonhydrogen atoms
were refined with anisotropic displacement parameters during the final
cycles. Hydrogen atoms were placed in calculated positions with isotropic
displacement parameters set to 1.2 3 Ueq of the attached atom.
The synthesis pathway is shown in Figure 2.
Cell Culture, cDNA Constructs, and Transfection
All GPCRs used in this study were amplified from human cDNA library
(Clontech) and cloned into pcDNA 3.1(2) (Invitrogen). Human embryonic
kidney-293 T cells (HEK293T) were cultured in Dulbecco’s minimum essen-
tialmedium supplementedwith 10% fetal bovine serum. The stable cell lines
expressing human opioid receptors m, d, and k were created as previously
reported [33]. The Individual dopamine receptors D1, D2, D3, D4, and D5
were transiently cotransfected with Ga15 in HEK293T cells using lipofect-
amine as described in Invitrogen’s protocol.
Ca2+ Response Monitored by Fluorometric Imaging Plate Reader Assay
The assay was performed as reported earlier [34]. The samples, which were
redissolved in dimethyl sulfoxide and stored in 96-well drug plates, were
diluted with fluorometric imaging plate reader (FLIPR) buffer and then auto-
matically added into the cells within 4 s. For agonist tests, the intracellular
Ca2+ concentration was monitored at 520 nm with excitation wavelength
at 488 nm over a period of 4 min. For antagonist tests, the compound was
first incubated with the cell for 10 min, before the addition of dopamine
with EC50 dose determined in individual dopamine receptor expressing
cell lines. Data were expressed as fluorescence (arbitrary units) versus time.
Antinociceptive Assays
Male CD1 mice (30–40 g, age 9–11 weeks) were used in the majority of the
experiments. Male 129/sv mice (20–30 g, age 9–12 weeks) were used in
Von Frey filament and hot box assays. D2KO mice (25–35 g, age 12–
13 weeks) were also used in the tail-flick assay. Age-matched wild-type
littermateswith the same genetic backgroundwere used as control animals.
The generation of D2KO mice was reported previously [35]. Saline,
morphine (10 mg/kg), DHCB (5–40 mg/kg), or l-THP (5–40 mg/kg) was
injected intraperitoneally (5 ml/kg). Naloxone (1 mg/kg, 2.5 ml/kg, i.p.) was
injected right before drug administration. SKF-38393 (1 mg/kg, 5 ml/kg,
i.p.) or quinpirole (0.5 mg/kg, 5 ml/kg, i.p.) was injected 30 min before
DHCB. Inflammation was evoked by injection of 25 ml of 5% formalin solu-
tion into the dorsal surface of the right hind paw 15 min after drug adminis-
tration. The tail-flick, formalin paw test, Von Frey filaments test, and hot box
assay experiments were carried out as previously reported [20, 36, 37].
Detailed experimental procedures are described in the Supplemental
Experimental Procedures. All experimental procedures were approved by
the Institutional Animal Care and Use Committee of University of California,
Irvine and were performed in compliance with national and institutional
guidelines for the care and use of laboratory animals.
The tolerance study was performed by a repeated-injection schedule.
Mice were injected (5 ml/kg, i.p.) with saline, morphine, or DHCB at dose
A Novel Analgesic Isolated from a TCM
123of 10 mg/kg once daily for 7 consecutive days. The loss of the antinocicep-
tive effects of drugs in the tail-flick test was used to assess the degree of
tolerance. The tail-flick latency was assessed on days 1, 3, 5, and 7 at
30 min after the drug injections.
Data analysis
Graphpad Prism 5.0 (GraphPad Software) was used for statistical analysis.
Data are means 6 SEM. Results were analyzed by ANOVA (one-way or
two-way) followed by the appropriate post hoc comparisons, and p < 0.05
was considered statistically significant.
Supplemental Information
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, and two figures and can be found with this article
online at http://dx.doi.org/10.1016/j.cub.2013.11.039.
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